RI-002
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Immune Deficiency Disorder
Conditions
Primary Immune Deficiency Disorder
Trial Timeline
Feb 1, 2014 → Jan 1, 2015
NCT ID
NCT01814800About RI-002
RI-002 is a phase 3 stage product being developed by ADMA Biologics for Primary Immune Deficiency Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01814800. Target conditions include Primary Immune Deficiency Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01814800 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Immune Deficiency Disorder